ZYUS Life Sciences Corporation
0.60
USD
+0.02
(+3.68%)
ISIN
CA9899601095
CUSIP
989960109
Return %
Stock
S&P 500
1Y
11.11
14.20
3Y
-10.45
81.12
5Y
- -
68.34
Capital Structure
CAD
•
in mil. unless spec.Working Capital
CAD
•
in mil. unless spec.Growth Rates
CAD
•
in mil. unless spec.Quarterly Revenue
CAD
•
in mil. unless spec.Quarterly Earnings Per Share
CAD
•
in mil. unless spec.Quarterly Dividends Per Share
CAD
•
in mil. unless spec.Company Description
- CEO
- Brent Harold Zettl
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Saskatoon Canada
- IPO Date
- Oct 18, 2000
- Website
- zyus.com
- Similar Companies
- Business
- ZYUS Life Sciences Corporation is a Canada-based, clinical-stage life sciences company engaged in the research, development, and commercialization of novel non-opioid, cannabinoid-based pharmaceutical drug candidates and medical therapeutics for the management of chronic and neuropathic pain. Founded in 2018 and headquartered in Saskatoon, Saskatchewan, the company operates through two primary segments: Pharmaceutical Drug Development and Commercial Medical Therapeutics. The company's product and service portfolio comprises: clinical-stage pharmaceutical candidates, including lead drug candidate Trichomylin softgel capsules, a proprietary fixed-dose cannabinoid formulation containing cannabichromene designed to treat moderate-to-severe cancer-related pain and musculoskeletal conditions; foundational medical therapeutics marketed under the Zylem brand, featuring standardized oral cannabinoid oils such as Zylem 1:20, Zylem 10:10, and Zylem 20:1 formulations; oral solid dosage forms, including Zylem 5:5 balanced softgel capsules; topical therapeutic preparations, consisting of cannabinoid-infused creams for localized pain relief; and specialized extraction, processing, analytical testing, and formulation services conducted at its Saskatoon-based processing facility designed to cGMP standards. ZYUS Life Sciences serves patients, healthcare practitioners, and medical distributors primarily in Canada, with export and international supply channels extending to overseas medical markets including Australia and Europe. In recent operational developments, the company completed a reverse takeover of Phoenix Canada Oil Company Limited to secure its public listing on the TSX Venture Exchange under the ticker ZYUS; completed patient visits in its Phase 2a UTOPIA-1 clinical trial evaluating Trichomylin in advanced cancer patients; expanded its intellectual property portfolio through the grant of U.S. Patent No. 12,616,704 covering proprietary cannabichromene formulations; executed a strategic corporate and operational realignment to prioritize core clinical-stage assets; and secured targeted debt financing facilities to strengthen working capital and fund ongoing regulatory and clinical milestones.